GlaxoSmithKline Plc.

Andrew Witty was named CEO designate for GSK in October 2007 and assumed the position of Chief Executive Officer on 21 May 2008. He is a member of the Board and Corporate Executive Team and previously held the role of President, Pharmaceuticals Europe, for five years. Andrew joined Glaxo in 1985 and held a variety of roles in the UK business. He was a Sales Representative for the Respiratory business, held a variety of Marketing roles and was Director of Pharmacy and Distribution. He has worked in the Company’s International New Products groups, both in the Respiratory and HIV/Infectious disease fields and has been involved in multiple new product development programmes. In 1993, Andrew was appointed Managing Director of Glaxo South Africa and later Area Director for GlaxoWellcome, South and East Africa. Subsequently he moved to North Carolina as Vice President and General Manager, Marketing for GlaxoWellcome Inc., the group’s US subsidiary. Andrew then moved to Singapore and led the Group’s operations in Asia as Senior Vice President, Asia Pacific prior to his appointment to the Corporate Executive Team as President of GSK Europe in 2003. While in Singapore Andrew was a Board Member of the Singapore Economic Development Board, the Singapore Land Authority and in 2003 was awarded the Public Service Medal by the Government of Singapore. Andrew has served in numerous advisory roles to Governments around the world including South Africa, Singapore, Guangzhou China and the UK. Andrew is currently a Non-Executive Director of the UK’s Office for Strategic Co-ordination of Health Research, sits on the Imperial College Commercialisation Advisory Board, is a member of the Health Innovation Council and is a member of INSEAD UK Council. He is also a member of the Business Council for Britain, a Board Member of PhRMA, a Vice-President of EFPIA and a Member of the Singapore Economic Development Board's International Advisory Council. Andrew has a Joint Honours BA in Economics from the University of Nottingham.

Abbas Hussain, President, Emerging Markets joined GSK on 2 June. He was previously President, Europe for Eli Lilly and Company. Prior to this, Abbas was Vice President of Europe with specific responsibility for the Western European Mid-Size countries, Africa & Middle East Area/Commonwealth of Independent States and Central & Eastern Europe regions. Abbas joined Lilly UK in 1988 as Sales Representative GP & Hospital Sales East London. He then moved to Australia in 1990, where he became Associate of Market Research & New Product Planning and subsequently District Sales Manager. In 1994, he moved to Indianapolis as Associate of Global Product Planning (Cardiovascular Business Unit), becoming Associate of Business Development Asia Pacific the following year. He took on the role of Pharmaceutical Sales & Marketing Director in India in 1996, and Managing Director of Turkey in 1998. Abbas moved to Germany in 2001 as General Manager, Lilly Deutschland as well as General Manager and Speaker, Lilly Pharma Holding GmbH. He was appointed European Mid-Size Area Director in 2003. Born in Madras, India, Abbas has a degree in Medicinal Chemistry & Pharmacology from Loughborough University of Technology, UK.

David Pulman took up the position of President, Global Manufacturing and Supply (GMS), GlaxoSmithKline in December 2002. He is a member of the Corporate executive team. Previously, he held the position of Senior Vice President - Strategy, Logistics and North American Supply, GMS, GSK, since January 2001. David has a broad range of manufacturing experience, having had responsibility for global primary manufacturing and for secondary manufacturing operations on five continents. Prior to this appointment, David had responsibility for North American Supply, GMS Global logistics and strategy, and for the team leading and monitoring the Global supply network programme. From December 2000, David was Senior Vice President, Europe supply, GMS responsible for the supply of drug product from the 17 sites in the region. He was previously Regional Supply Director, Europe, Middle East and Africa for GW. From March 2000, David worked as a member of the merger integration team, with responsibility for facilitating international commercial. David joined Glaxo in 1978. During the following years, he held increasingly responsible roles in both the manufacturing site network and the central functions. In 1994 he was appointed Director, Manufacturing strategy where he co-ordinated the worldwide integration of Glaxo and Wellcome manufacturing activities. He has a PhD in microbiology from Newcastle University.

Eddie Gray became responsible for the Group’s operations in Europe in January 2008. He is a member of the Corporate Executive Team. Previously he held the role of Senior Vice President and General Manager, Pharmaceuticals UK. Eddie was appointed Senior Vice President and General Manager, Pharmaceuticals UK in 2001. Prior to that he was Vice President & General Manager, SmithKline Beecham Pharmaceuticals, Canada, and a member of SmithKline Beecham’s Executive Management Team for North America. He joined SmithKline Beecham in 1988 and held various positions of increasing responsibility, including Head of Hospital Sales, Marketing Manager for Anti-Infective products and Business Unit Director for the UK Pharmaceuticals General Medicine business before moving to the US, where he assumed responsibility for Market Research for the US Pharmaceuticals business. He later became Vice President & Director of Anti-Infectives Marketing, then Vaccines Marketing in the US, before assuming his role in Canada. Eddie is an advisory board member of Opportunity Now, an organisation for employers who are committed to creating an inclusive workplace for women, and is also a Director of the British Pharma Group. He holds an honours degree in Chemistry and Management Studies from the University of London, and an MBA from the Cranfield School of Management in the UK. He is married with three daughters.

John Clarke assumed the role of President, Consumer Healthcare, GlaxoSmithKline in January 2006. He is a member of the Corporate Executive Team. John was previously the President of the GSK Consumer Healthcare Futures Group. John joined Beecham in 1976 and progressed through a number of marketing and General Manager roles in Australasia, South Africa, The Far East, Japan, Canada and the UK. In 1996, John was appointed General Manager of the nutritional healthcare business. From 1998 to 2003, John was President, Consumer Healthcare Europe, and in 2004, appointed President, Futures Group. John received a triple-major Bachelor of Commerce degree from Otago University, New Zealand.

Marc Dunoyer was made responsible for the new Asia Pacific region, encompassing all the countries in this area, including Japan and Australia in May 2008. He served as President, Pharmaceuticals Japan for GlaxoSmithKline since March 2003. He is a member of the Corporate Executive Team. Previously, he held the role of Senior Vice President and Regional Director, Japan. Marc joined the company from Hoechst Marion Roussel in 1999 as Senior vice president, Japan, and was appointed to his current role in 2000. Marc has an MBA from the Hautes Etudes Commerciales. He has a Bachelor of Law degree from Paris University and also qualified as a Junior CPA in France in 1977.

Bill Louv was appointed Senior Vice President, Information Technology and Chief Information Officer for GlaxoSmithKline in January 2007. He is a member of the Corporate Executive Team. He was previously Senior Vice President, Information Technology for the company's Research & Development function. Bill joined the Glaxo Inc. in 1994 as Vice President of Medical Data Sciences, and has held a number of increasingly senior roles in R&D and IT, including Senior Vice President, Information Technology for the company's US Pharmaceuticals business. Prior to joining the company, Bill held positions of increasing responsibility at Marion Merrell Dow including Vice President of Global Statistics and Clinical Data Management. Prior to joining the pharmaceutical industry, he was an associate professor of epidemiology and biostatistics at the University of Alabama Medical Center. Bill has a Bachelor of Science degree in Biology from the College of William and Mary, and Master of Science and Doctor of Philosophy degrees in Statistics from the University of Florida. Bill has held memberships in a variety of public health and statistical organisations and published articles in over 25 professional journals.

Dan Phelan became Chief of Staff with primary responsibility for leading the critical support functions for GSK in May 2008. He is a member of the Corporate Executive Team. He was Senior Vice President, Human Resources, GlaxoSmithKline since January 2001. Previously, he had held the same position in SmithKline Beecham. Dan joined the company as Manager of Labour Relations in 1981 and, in 1986, was named Vice President, Employee Relations. In 1987, he became Vice President, Human Resources and, in 1989, was appointed Vice President and Director Personnel-US, Pharmaceuticals. He later became Senior Vice President and Director, Operations and Administration, Research & Development. Dan is an honours graduate of Rutgers University, New Jersey. He served as an officer in the US Army Medical Service Corps, returning to Ohio State University for a Master's degree in higher education administration. He was a director in the Office of Student Services at Ohio State for three years. He returned to Rutgers, where he earned a Law degree. Following an internship with the National Labor Relations Board and a clerkship with the Chief Judge of the US Federal District Court in New Jersey, he joined the labour department of a major Philadelphia law firm. He is admitted to practice in New Jersey and Pennsylvania. Dan is a member of the Board of Directors of Tyco Electronics. He is also a member of the Dean's Advisory Council at Rutgers School of Law-Camden.

David Redfern was appointed Chief Strategy Officer in May 2008 and is responsible for proactive exploration of new business opportunities and strategic planning. Previously, he was Senior Vice President, Northern Europe with responsibility for managing GSK's pharmaceutical businesses in Denmark, Finland, Iceland, Ireland, the Netherlands, Norway, Sweden and Switzerland. David joined GSK in 1994 from PricewaterhouseCoopers, where he managed a portfolio of audit clients and corporate transactions. He began his career with GSK as Corporate Accounts Manager, and spent 4 years in the Corporate Development team before being appointed Senior Vice President and Chief Financial Officer of Pharma Europe in 1999. He was appointed Senior Vice President & Area Director, Central Europe in 2003, where he successfully led the Central Europe markets through their transition into the EU. David has a Bachelor of Science degree from Bristol University in the UK and is a Chartered Accountant.

Julian Heslop assumed the role of Chief Financial Officer for GlaxoSmithKline in April 2005. Previously, Julian served as Senior Vice President, Operations Controller. In this role, he was a member of the pharmaceutical operating committee and chaired the capital review team. He was appointed to this position following the merger of Glaxo Wellcome and SmithKline Beecham in January 2001, prior to which he was Financial Controller of Glaxo Wellcome. Julian qualified as a chartered accountant in 1977 whilst working for John M Winter. In 1978 he joined Stoy Hayward as an auditor. He moved to Imperial Brewing and Leisure in 1979 where he worked in a number of management accounting and strategic planning roles. He joined Grand Metropolitan in1986 and held a number of senior roles in their brewing, property and food businesses and was latterly Group Controller. He joined Glaxo Wellcome in 1998.

Claire Thomas, Senior Vice President, Human Resources was previously Senior Vice President, Human Resources, Pharmaceuticals International. Claire joined the company in 1996 as Senior Manager, Human Resources, Sales and Marketing Group, UK Pharmaceuticals before becoming Director of Human Resources for UK Pharmaceuticals in 1997. She was appointed Senior Vice President, Human Resources, Pharmaceuticals Europe in 2001, where she successfully led the HR function through the merger. From 2003 to 2006, Claire played a key strategic role in the radical redesign and delivery of the New Operating Model within Pharma Europe. Prior to joining the company she worked for Ford Motor Company, holding various positions including HR Supervisor Dagenham Assembly Plant, HR Supervisor Sales & Marketing UK and Central Europe, and OD Manager European Engineering. Claire has a Bachelor of Science degree in Economics, Management and Industrial Relations from the University of Wales. Claire was honoured as an Outstanding European Woman of Achievement in 2007.

Duncan Learmouth was appointed Senior Vice President, Corporate Communications and Community Partnerships in July 2006. He is a member of the Corporate Executive Team. He was previously Vice President, Global Investor Relations and Competitive Excellence. Duncan joined Glaxo Wellcome in 1991 and joined the Investor Relations department in 1997. In December 2000, after the merger of Glaxo Wellcome and SmithKline Beecham he was appointed Vice President of Investor Relations. In November 2001 he was appointed Vice President, Global Investor Relations with responsibility for the global IR function, reporting to the CFO. In February 2006 he added the competitive excellence function to his responsibilities, which reports to the CEO, and includes the role of secretary to the CET, GSK's Executive Committee. Prior to Investor Relations, Duncan was a Senior Financial Analyst within the Corporate Finance department responsible for the Group's strategic plan. He has also been Financial Controller of Adechsa SA based in Zug, Switzerland and worked in the Financial Investigations and Trading Arrangements departments, both also part of Corporate Finance. Before moving to Glaxo Wellcome, Duncan was with Deloitte and Touche in London from 1988, qualifying as a Chartered Accountant in 1991. Duncan was educated at Durham University where he gained a degree in Chemistry.

Simon Bicknell, Senior Vice President, Company Secretary & Compliance Officer was appointed Company Secretary for GSK in 2000, and Compliance Officer in 2006. Simon joined the Company Secretariat in 1984. He was appointed Deputy Secretary of Glaxo Wellcome in 1995 and Company Secretary of GlaxoSmithKline plc in 2000. He is responsible for risk management, compliance and strategic auditing and chairs the company's Risk Oversight and Compliance Council. Simon works closely with GSK's Board of Directors in his capacity as Company Secretary. After gaining his Law degree, Simon qualified as a barrister in 1983 and is a member of MiddleTemple.

Linda Kollofski has served as the Company's Vice President of Domestic Marketing since February of 2004 and as Vice President of New Business Development from November of 2002 to January of 2004. Prior to joining the Company in 2002, Ms. Kollofski was principal of Linda K. Consulting, Inc. from October of 1994 to October of 2002. Ms. Kollofski provided marketing expertise to various businesses including Haagen-Daz, Totino's and Green Giant as well as to Telex Communications, Hazeldon Foundation publishing business and the Company's FiberChoice brand. Previously, Ms. Kollofski served in senior marketing and new business development positions with the Hazelden Foundation, Dow Brands, Pillsbury and Munsingwear.

Daniel E. Cohen has served as the Company's Chairman of the Board since 1993 and has served as a director of the Company since its formation in 1982. Mr. Cohen also served as the Company's Chief Executive Officer from 1989 to June 2001 and as Treasurer from 1982 to March 1999. Mr. Cohen, a founder of the Company, is a medical doctor and board-certified neurologist.

Dan Troy joined GSK as Senior Vice President & General Counsel in September 2008. Reporting to Andrew Witty, he is based in Franklin Plaza, Philadelphia PA, and is a member of the Corporate Executive Team. Previously a Partner at the Washington law firm Sidley Austin LLP, where he represented mainly pharmaceutical companies and trade associations on matters related to the US Food and Drug Administration (FDA) and government regulations, Dan was formerly Chief Counsel for the FDA, where he served as a primary liaison to the White House and the US Department of Health and Human Services (HHS). While leading an office of attorneys who reviewed and approved all major regulations and guidances, Dan oversaw the legislative implications of many of the most important issues facing the pharmaceutical industry today, including the reform of the Hatch-Waxman Act and subsequent legislative ratification. His office also approved and managed all agency litigation, and Dan established procedures for the FDA legal team to follow in preparing and then litigating high-profile cases.

Dr. Bloom is a founder of Alkermes and has been a director of Alkermes since 1987. Dr. Bloom has been active in neuropharmacology for more than 35 years, holding positions at Yale University, the National Institute of Mental Health and The Salk Institute. From 1983 to February 2005, Dr. Bloom was the Chairman of the Neuropharmacology Department at The Scripps Research Institute and is currently Professor Emeritus. Dr. Bloom served as Editor-in-Chief of Science from 1995 to May 2000. He holds an A.B. (Phi Beta Kappa) from Southern Methodist University and an M.D. (Alpha Omega Alpha) from Washington University School of Medicine in St. Louis. He is a member of the National Academy of Science, the Institute of Medicine, the Royal Swedish Academy of Science, the President's Council on Bioethics, Veteran's Administration - Gulf War Veteran Illness and the Washington University Board of Trustees. Dr. Bloom also serves on the Board of Directors of Elan Pharmaceuticals and the Scientific Advisory Boards of MiddleBrook Pharmaceuticals and RxGen.

Sir Crispin Davis (59) (British) Chief Executive Officer since 1999. Will retire in March 2009. Knighted in 2004 for services to the information industry. Non-executive director of GlaxoSmithKline plc and a member of the International Advisory Board, Citigroup. Prior to joining Reed Elsevier was Chief Executive Officer of Aegis Group plc. From 1990 to 1993 was a member of the main board at Guinness plc and Group Managing Director of United Distillers. Spent over 20 years at Procter and Gamble where he held senior positions in the UK and Germany, before heading up the North American Food Business.

Dr Podolsky is an Independent Non-Executive Director, Mallinkrodt Professor of Medicine and Chief of Gastroenterology at Massachusetts General Hospital and Harvard Medical School as well as Chief Academic Officer of Partners HealthCare System. He is a world-renowned researcher who has advanced knowledge of underlying mechanisms of disease and new therapies for gastrointestinal disorders. He is also an international authority on trefoil proteins and innate immunity. Dr. Podolsky has published and patented widely in his field. He is past editor-in-chief of Gastroenterology, the leading journal in the field, and is immediate Past President of the American Gastroenterological Association. Dr Podolsky is also Chairman of the Board & Scientific Co-Founder of the GI Company, a privately held, specialty biopharmaceutical company established to meet the clinical needs and commercial opportunities available in the field of gastrointestinal medicine.

James Murdoch has been Non-Executive Chairman of Sky since December 2007 and a director of the company since February 2003. He was Chief Executive between November 2003 and December 2007. James is Chairman and CEO, Europe and Asia, at News Corporation and is a member of News Corporation’s Board of Directors and Executive Committee. Between May 2000 and November 2003, he was Chairman and CEO of Star. James also serves on the Board of YankeeNets and the Board of Trustees of the Harvard Lampoon and attended Harvard University.

Independent Non-Executive Director. Mr Culp is President and Chief Executive Officer of Danaher Corporation. Prior to joining Danaher, he held positions in Accenture, previously Andersen Consulting.

Independent Non-Executive Director. Professor Anderson is the Professor of Infectious Disease Epidemiology in the Faculty of Medicine, Imperial College, London and, until 30 September 2007, the Chief Scientific Adviser at the Ministry of Defence in the United Kingdom. It was announced on 21 June 2007 that Professor Anderson will succeed Sir Richard Sykes as Rector of Imperial College in the summer of 2008. He is a Fellow of the Royal Society, a Fellow of the Academy of Medical Sciences, a Fellow of the Royal Statistical Society, Honorary Fellow of the Institute of Actuaries and a Foreign Associate Member of the Institute of Medicine at the US National Academy of Sciences. He has published over 450 scientific papers on the epidemiology, population biology, evolution and control of a wide variety of infectious disease agents, including HIV, BSE, vCJD, parasitic helminths and protozoa, and respiratory tract viral and bacterial infections. His principal research interests are epidemiology, biomathematics, demography, parasitology, immunology and health economics. He also has a keen interest in science policy and the public understanding of science. He received a Knighthood in the Queen's Birthday Honours in June 2006.

Sir Deryck Maughan joined KKR in 2005. He is Chairman of KKR Asia and a member of the Financial Services industry team. He serves on the board of directors of BlackRock, GlaxoSmithKline and Thomson Reuters. Sir Deryck was Vice Chairman of Citigroup from 1998 to 2004, Chairman and CEO of Salomon Brothers from 1992 to 1997, and Chairman of Salomon Brothers Asia from 1986 to 1991. He was a member of H. M. Treasury from 1969 to 1979. He is a former Vice Chairman of the New York Stock Exchange and Chairman of the U.S.-Japan Business Council. Sir Deryck is a Harkness Fellow and a graduate of King's College, University of London and Stanford University Graduate School of Business.

Independent Non-Executive Director. Dr Burns is Chairman, President and Chief Executive Officer of Dow Corning. She joined Dow Corning in 1983 as a researcher working on water based and high temperature elastomers. She became director of Women's Health in 1994 and subsequently moved into corporate management becoming Science and Technology Director for Europe in 1997. She was first elected to Dow Corning's Board of Directors in December 2000, she was then elected President and Chief Executive Officer in February 2003, Chief Operating Officer in January 2004 and Chairman in January 2006. Dr Burns holds a Ph.D. in organic chemistry, with an organosilicon specialty, from Iowa State University. She completed her post-doctoral studies at the Universite Montpellier, Sciences et Techniques du Languedoc, France. She is a board member of the American Chemical Society and The Conference Board and sits on the Executive Committee of the Society of Chemical Industry, and on the Board of Directors for the Society of Women's Health Research. She has also served on the Michigan Molecular Institute.

Appointed to the Board on 1 January 2006. Independent Non-Executive Director Tom de Swaan is a member of the Supervisory Board of VanLanschot Bankers. He was a member of the Managing Board and CFO of ABN AMRO, a member of the governing board of the Dutch Central Bank and Chairman of the Basel Committee on banking supervision. He is a member of the Board of Directors of Zurich Financial Services, Vice Chairman of the Supervisory Board and Chairman of the Audit Committee of Royal Ahold, and is a member of the Supervisory Board of Royal DSM. He is also a Non-Executive Director of the Financial Services Authority and a member of the Board of the Institute of International Finance. He holds a master degree in economics. In accordance with the Combined Code, the Board has determined that Mr de Swaan has recent and relevant financial experience. The Board has also agreed that Mr de Swaan has the appropriate qualifications and background to be an audit committee financial expert in accordance with the requirements of the Sarbanes-Oxley Act 2002. Mr de Swaan succeeded Dr Schmitz as Chairman of the Audit Committee with effect from 1 September 2006.